ESTROVIS Drug Patent Profile
✉ Email this page to a colleague
When do Estrovis patents expire, and when can generic versions of Estrovis launch?
Estrovis is a drug marketed by Parke Davis and is included in one NDA.
The generic ingredient in ESTROVIS is quinestrol. There is one drug master file entry for this compound. Additional details are available on the quinestrol profile page.
Summary for ESTROVIS
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 59 |
Patent Applications: | 1,810 |
DailyMed Link: | ESTROVIS at DailyMed |
US Patents and Regulatory Information for ESTROVIS
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Parke Davis | ESTROVIS | quinestrol | TABLET;ORAL | 016768-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Parke Davis | ESTROVIS | quinestrol | TABLET;ORAL | 016768-003 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |